Mylan Laboratories Limited

Other

Mylan Labs Limited

Arabinda Sahu

Siva Rama Prasad Vellanki

Debashish Datta

Nitin Ashok Shimpi

Ramakoteswara Rao Jetti

Lakshmana Rao Vadali

Aggi Ramireddy Bommareddy

Neelima Bhagavatula

Raja Babu Balusu

Srikanth Sarat Chandra Gorantla

Nagaraju Mittapelly

Shankar Rama

Srinivasa Rao Dasari

Vikram Vanama

Satishbabu Kothari

Sivaram Prasad Vellanki

Venkata Suryanarayana Ponnekanti

Aravind Kumar Katukuri

Hari Babu Nandipati

Mastan Rao Ravi

Satish Babu Kothari

Anil Ponnuru

Siva Rama Prasad Vellenki

Ravindrababu Kilaru

Naveen Kumar Phadhuri

Lakshmana Rao Ampolu

Siva Koteswara Rao Prathi

Vellanki Sivaram Prasad

Ankama Nayudu Annadasu

Siva Rama Vellenki

Anil Kumar Ponnuru

Siva Rama Vellanki

Venkata Srimannarayana Deevi

Naveen Kumar Phaduri

Rajababu Balusu

The amorphous form of trisodium sacubitril valsartan and methods for the preparation thereof are disclosed herein.

Amorphous trisodium sacubitril valsartan and a process for the preparation thereof

The present invention relates to a non-solvated crystalline Darunavir, process for its preparation and pharmaceutical composition comprising it. The present invention also relates to a process for the preparation of amorphous Darunavir from a non-solvated crystalline Darunavir.

Crystalline Darunavir

The present invention relates to a novel process for the preparation of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol of formula I by reacting a compound of formula VII with the compound of formula R2-OH in the presence of haloginating agent to obtain a compound of formula VI and treating a compound of formula VI with dehaloginating agent to obtain a compound of formula V by reducing a compound of formula V, followed by cylization to obtain compound of formula IV and separating the enantiomer and diastereomers from compound of formula IV to yield a compound of formula I. Compound of formula I is useful as an intermediate in the preparation of protease inhibitors, in particular broad spectrum HIV protease inhibitors, the present invention also relates to process for the preparation of Darunavir from (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol.

Process for the preparation of (3R, 3aS, 6aR)-hexahydrofuro [2, 3-b] furan-3-ol

The present invention relates to an improved process for the preparation of Tenofovir Disoproxil and its pharmaceutically acceptable salts comprising the steps of: a) esterifying Tenofovir with chloromethyl isopropyl carbonate in presence of a base, phase transfer catalyst and optionally dehydrating agent, in a suitable solvent; b) optionally purifying Tenofovir Disoproxil; and c) converting of Tenofovir Disoproxil into its pharmaceutically acceptable salts. The present invention further relates to a process for the preparation of Tenofovir by reacting 1-(6-amino-purin-9-yl)-propan-2-ol with toluene-4-sulfonic acid diethoxy phosphoryl methyl ester in presence of a base in a non-polar solvent medium followed by hydrolysis.

Process for the preparation of tenofovir disoproxil fumarate

A process for the preparation of Darunavir comprises the reacting of 4-amino-N-(2R, 3S) (3-amino-2-hydroxy-4-phenylbutyl)-N-isobutyl-benzenesulfonamide with (3R, 3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol derivative in N-methyl-2-pyrrolidinone and isolating the resulting Darunavir. The process yields Darunavir with a very low level of the difuranyl impurity.

Process for the preparation of darunavir

Growing community of inventors

Hyderabad Telangana, India

Arabinda Sahu